260 related articles for article (PubMed ID: 32285623)
21. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability.
Garamendi-Ruiz I; García-García ME; Bertol-Alegre V; Mauri-Llerda JÁ; García-Morales I; Garayoa-Irigoyen V; Agúndez-Sarasola M; De Toledo-Heras M; García-Morales V; García-Gomara MJ; Arcos-Sánchez C; Gago-Veiga A; Escalza-Cortina I; Rueda-Mena E; Muñoz-Fargas E; Santos-Lasaosa S; Oliván-Usieto JA; Julián LD; Gómez-Esteban JC; Marinas-Alejo A
Epileptic Disord; 2016 Jun; 18(2):173-80. PubMed ID: 27238234
[TBL] [Abstract][Full Text] [Related]
22. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability.
Maschio M; Dinapoli L; Mingoia M; Sperati F; Pace A; Pompili A; Carapella CM; Vidiri A; Muti P
J Neurol; 2011 Nov; 258(11):2100-4. PubMed ID: 21674196
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report.
Maschio M; Dinapoli L; Saveriano F; Pompili A; Carapella CM; Vidiri A; Jandolo B
Acta Neurol Scand; 2009 Sep; 120(3):210-2. PubMed ID: 19719809
[TBL] [Abstract][Full Text] [Related]
24. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
[TBL] [Abstract][Full Text] [Related]
25. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of perampanel as an add-on therapy in patients with epilepsy.
Arai Y; Inaji M; Shimizu K; Kondo S; Hashimoto-Fujimoto S; Kiyokawa J; Kawano Y; Yamamoto S; Maehara T
Epilepsy Res; 2024 Feb; 200():107307. PubMed ID: 38286107
[TBL] [Abstract][Full Text] [Related]
27. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C
J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
[TBL] [Abstract][Full Text] [Related]
29. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T
Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440
[TBL] [Abstract][Full Text] [Related]
30. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
Gil-López FJ; Montoya J; Falip M; Aparicio J; López-González FJ; Toledano R; Gil-Nagel A; Molins A; García I; Serrano P; Domenech G; Torres F; Donaire A; Carreño M
Acta Neurol Scand; 2018 Aug; 138(2):122-129. PubMed ID: 29573400
[TBL] [Abstract][Full Text] [Related]
31. The impact of perampanel treatment on quality of life and psychiatric symptoms in patients with drug-resistant focal epilepsy: An observational study in Italy.
Deleo F; Quintas R; Turner K; Didato G; Zambrelli E; Pappalardo I; Chiesa V; Pastori C; de Curtis M; Canevini MP; Villani F
Epilepsy Behav; 2019 Oct; 99():106391. PubMed ID: 31371205
[TBL] [Abstract][Full Text] [Related]
32. Perampanel in Brain Tumor-Related Epilepsy: A Systematic Review.
Tabaee Damavandi P; Pasini F; Fanella G; Cereda GS; Mainini G; DiFrancesco JC; Trinka E; Lattanzi S
Brain Sci; 2023 Feb; 13(2):. PubMed ID: 36831869
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
34. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
35. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
[TBL] [Abstract][Full Text] [Related]
36. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
[TBL] [Abstract][Full Text] [Related]
37. Perampanel: A Review in Drug-Resistant Epilepsy.
Frampton JE
Drugs; 2015 Sep; 75(14):1657-68. PubMed ID: 26370209
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
39. Epilepsy in patients with primary brain tumors: The impact on mood, cognition, and HRQOL.
Rahman Z; Wong CH; Dexter M; Olsson G; Wong M; Gebsky V; Nahar N; Wood A; Byth K; King M; Bleasel AB
Epilepsy Behav; 2015 Jul; 48():88-95. PubMed ID: 26136184
[TBL] [Abstract][Full Text] [Related]
40. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E
Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
